BioLineRx is trading at $2.17, up 6.70%, with no October 22 company-specific catalyst identified.
- BioLineRx’s investor-relations press-release page lists an October 8 release as its latest announcement.
- The broader market was lower, but available evidence does not establish it as the reason for the gain.